Dr Reddy's Laboratories up 2% on phase-2 trial of CA-170

The company's wholly owned subsidiary Aurigene Discovery Technologies is planning to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India.

September 13, 2017 / 11:15 IST

Representative image.

26 Aug, 2025 12:21

Volume

Todays L/H

Shares of Dr Reddy's Laboratories added 2 percent intraday Wednesday as the company is planning for phase 2 trial of CA-170.

The company's wholly owned subsidiary Aurigene Discovery Technologies is planning to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India.

CA-170 is an oral small molecule targeting the immune checkpoints PDL1 and VISTA.

The phase 2 trial is a result of the initial safety data and preliminary evidence of clinical benefit observed in the trial.

At 10:48 hrs Dr Reddy’s Laboratories was quoting at Rs 2,212.40, up Rs 47.60, or 2.20 percent on the BSE.

Posted by Rakesh Patil

first published: Sep 13, 2017 10:53 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347